A month at IHI - a word from our director
I sit down to write this introduction after my first full month as Executive Director. It has been a month of learning – about the programme, our projects, and our organisation, but above all about the work of everyone involved in IHI and their commitment to the initiative.
The articles in this month’s newsletter highlight how the ‘innovative’ in Innovative Health Initiative doesn’t just refer to our research and the outcomes, but also to the way we are driving new collaborations across sectors and between stakeholder groups. The new IHI project PREDICTOM exemplifies how we are applying this approach to the challenge of finding methods for the early diagnosis of Alzheimer’s. The partners come from medical technology, artificial intelligence, medicine, aging research, and from academia, healthcare, and small and large companies.
PREDICTOM also demonstrates another strength of IHI – the way it builds on the experiences and successes of IMI. PREDICTOM joins an impressive portfolio of projects addressing Alzheimer’s and other neurological disorders. We report on one of these, EPND, which has discovered novel molecular subtypes in Alzheimer’s disease and is establishing a large, transnational reference dataset.
The strength of this ecosystem we are creating via our projects is evident in a steady stream of new publications from long-finished projects, and this month I enjoyed reading about the outcomes from the CANCER-ID project. I hope you will find it as interesting as I did.
Niklas Blomberg, IHI Executive Director
The articles in this month’s newsletter highlight how the ‘innovative’ in Innovative Health Initiative doesn’t just refer to our research and the outcomes, but also to the way we are driving new collaborations across sectors and between stakeholder groups. The new IHI project PREDICTOM exemplifies how we are applying this approach to the challenge of finding methods for the early diagnosis of Alzheimer’s. The partners come from medical technology, artificial intelligence, medicine, aging research, and from academia, healthcare, and small and large companies.
PREDICTOM also demonstrates another strength of IHI – the way it builds on the experiences and successes of IMI. PREDICTOM joins an impressive portfolio of projects addressing Alzheimer’s and other neurological disorders. We report on one of these, EPND, which has discovered novel molecular subtypes in Alzheimer’s disease and is establishing a large, transnational reference dataset.
The strength of this ecosystem we are creating via our projects is evident in a steady stream of new publications from long-finished projects, and this month I enjoyed reading about the outcomes from the CANCER-ID project. I hope you will find it as interesting as I did.
Niklas Blomberg, IHI Executive Director
PREDICTOM plans platform to screen for dementia risk
The new IHI project wants to identify people at risk of dementia, before the first symptoms appear, when there is still time to take steps to slow the progress of the disease.
Read more
EDENT1FI pioneers new approach to type 1 diabetes diagnosis and care
New IHI project EDENT1FI aims to improve our ability to detect type 1 diabetes in children and adolescents before the body’s insulin-producing cells have been badly damaged.
New IHI project hopes to boost access to innovative medical technologies in the EU
HEU-EFS aims to develop a harmonised approach to early feasibility studies (EFS) for medical devices in the EU, a key step in the early development of new devices.
Discovery of five subtypes of Alzheimer’s enriches the EPND database
The work illustrates the benefit of large datasets such as the EPND database to find important patterns in biological data.
Read more
Resistance to lung cancer treatment examined by CANCER-ID
IMI project CANCER-ID applied molecular techniques to investigate whether mutant cells were causing patients to reject a commonly-used combination therapy for lung cancer.
Categorising people according to ‘immunotype’ could predict vaccine effectiveness
The VITAL project analysed and classified people according to their immune system profiles to evaluate their response to influenza vaccination.
Meet the IHI team at DIA Europe in Brussels
Meet IHI at the DIA Europe exhibition from 12 to 14 March and find out more about our work during a dedicated session on IHI at midday on 13 March.
Read more
IHI celebrates the International Day of Women and Girls in Science
For the International Day of Women and Girls in Science on 11 February, we spoke to some of the women working with IHI and IMI to hear how funding organisations can help women to thrive.
Got a question about our calls? The answer is probably on our website!
Got a question about our calls for proposals? Visit our call documents page and check the Guide for Applicants and FAQs – you will probably find your answer there!